Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment

Prostate cancer is an increasing threat throughout the world. As a result of a demographic shift in population, the number of men at risk for developing prostate cancer is growing rapidly. For 2002, an estimated 189,000 prostate cancer cases were diagnosed in the U.S., accompanied by an estimated 30...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular biochemistry 2004-02, Vol.91 (3), p.459-477
Main Authors: De Marzo, Angelo M., DeWeese, Theodore L., Platz, Elizabeth A., Meeker, Alan K., Nakayama, Masashi, Epstein, Jonathan I., Isaacs, William B., Nelson, William G.
Format: Article
Language:English
Subjects:
Atrophy - physiopathology
benign prostatic hyperplasia
DNA-Binding Proteins
Gene Expression Regulation, Neoplastic
Genes, Tumor Suppressor
Homeodomain Proteins - genetics
Humans
inflammation
Inflammation - physiopathology
Male
Phosphoproteins - genetics
Phosphoric Monoester Hydrolases - genetics
prostate cancer
prostateatrophy
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
prostatitis
Proteins - genetics
PTEN Phosphohydrolase
Racemases and Epimerases - genetics
Receptors, Androgen - genetics
Serine Endopeptidases - genetics
Signal Transduction
Telomere - genetics
Telomere - physiology
Trans-Activators - genetics
Transcription Factors - genetics
Tumor Suppressor Proteins - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate cancer is an increasing threat throughout the world. As a result of a demographic shift in population, the number of men at risk for developing prostate cancer is growing rapidly. For 2002, an estimated 189,000 prostate cancer cases were diagnosed in the U.S., accompanied by an estimated 30,200 prostate cancer deaths [Jemal et al., 2002]. Most prostate cancer is now diagnosed in men who were biopsied as a result of an elevated serum PSA (>4 ng/ml) level detected following routine screening. Autopsy studies [Breslow et al., 1977; Yatani et al., 1982; Sakr et al., 1993], and the recent results of the Prostate Cancer Prevention Trial (PCPT) [Thompson et al., 2003], a large scale clinical trial where all men entered the trial without an elevated PSA (
ISSN:0730-2312
1097-4644
DOI:10.1002/jcb.10747